NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
Nano-X Imaging Ltd. (NNOX) CEO and director Erez Meltzer indirectly purchased 25,000 ordinary shares on October 19, 2026, at $0.45 per share through Oud Nof, a company wholly owned by him. Oud Nof held 90,443 shares after the purchase. No Rule 10b5-1 plan is reported. The report separately lists 60,584 ordinary shares held directly as of October 19, 2026, and three direct option positions.
Nano-X Imaging Ltd. (NNOX) expects preliminary, unaudited third-quarter 2026 revenue of approximately $4.3–$4.4 million, compared with $3.4 million in third-quarter 2025. Teleradiology revenue was approximately $3.1 million in both periods; imaging-system sales, deployment and OEM services were approximately $0.3 million versus $0.2 million, while AI and software revenue was $1.0 million versus $0.1 million. The company attributed the AI and software increase mainly to consolidation of Vaso Healthcare IT Inc., now Nanox Health IT Inc.
Nanox AI entered a distribution agreement with Technologic s., an affiliate of Tecnologie Avanzate, to commercialize its Bone Solution in Italy; Nanox.ARC X was selected as one of TIME’s Best Inventions of 2026. Cash, cash equivalents, short-term deposits and long-term restricted deposits were expected to total approximately $26.0 million as of September 30, 2026, versus $60.0 million as of December 31, 2025. Nanox said this balance was insufficient to support current operating plans for at least one year from October 16, 2026, raising substantial doubt about its ability to continue as a going concern. The preliminary figures remain subject to closing procedures, adjustments and review; the independent auditor has not audited or reviewed them.
Nano-X Imaging Ltd. granted Chief Corporate Resources Attias Gali Yahav 28,283 ordinary shares represented by restricted share units on October 14, 2026, under its 2019 Equity Incentive Plan. The units vest in four equal semi-annual installments of 25% each on February 13, 2027, August 13, 2027, February 13, 2028, and August 13, 2028, subject to his continuous employment on each vesting date. As of October 14, 2026, he also held directly options for 6,500 ordinary shares at an exercise price of $23.86, expiring September 30, 2031; 12,500 ordinary shares at $17.63, expiring March 28, 2032; and 40,000 ordinary shares at $11.52, expiring May 23, 2033. The 6,500-share and 12,500-share options were fully vested and exercisable.
Nano-X Imaging Ltd.’s board granted its General Manager AI Division, Sharon Saban, 28,283 ordinary shares represented by restricted share units (RSUs) on October 14, 2026, under the 2019 Equity Incentive Plan. The RSUs vest and settle in four equal semiannual installments of 25% following an August 13, 2026 vesting commencement date, subject to Saban’s continuous employment on each applicable date; all underlying shares are to be issued by August 13, 2028. A separate RSU holding from a February 5, 2026 grant is scheduled to vest 50% on February 5, 2027, and 50% on February 5, 2028. Saban also held 15,000 fully vested and exercisable options to buy ordinary shares at $17.63 each, expiring September 15, 2032.
Nano-X Imaging Ltd. reported that its board granted CFO Guy Nathansohn 50,000 restricted share units (RSUs) representing 50,000 ordinary shares on October 14, 2026. The award is scheduled to vest and settle in two 25,000-unit installments on October 14, 2027 and October 14, 2028, subject in each case to his continuous employment on the applicable vesting date. A separate informational holding entry lists 50,000 RSUs granted July 15, 2026, with 25,000-unit installments scheduled for July 15, 2027 and July 15, 2028, subject to the same employment condition.
Nano-X Imaging Ltd. granted Chief Legal Officer Feler Marina Gofman 28,283 restricted share units on October 13, 2026, under its 2019 Equity Incentive Plan. The units vest and settle for ordinary shares in four equal semi-annual installments of 25% each, on February 13, 2027, August 13, 2027, February 13, 2028, and August 13, 2028, subject in each case to her continuous employment. Separate informational holdings list direct options covering 15,000, 10,000, and 30,000 ordinary shares.
Nano-X Imaging Ltd. officer Dara James, whose title is GM Source & Services Division, received a grant of 28,283 restricted share units (RSUs) on October 11, 2026, under the 2019 Equity Incentive Plan. The RSUs vest and settle for ordinary shares in four equal semi-annual installments of 25% on February 13, 2027, August 13, 2027, February 13, 2028 and August 13, 2028, subject in each case to Dara James’s continued employment by Nano-X Imaging Ltd.
Nano-X Imaging Ltd. General Manager, ARC Division Ofir Koren received a grant of 28,283 ordinary shares represented by RSUs on October 10, 2026, under the 2019 Equity Incentive Plan. The RSUs vest in four equal semi-annual installments beginning February 13, 2027, subject to continuous employment on each vesting date. Koren also reported direct options covering 100,000 ordinary shares at a $49.68 exercise price, 25,000 at $17.63, and 33,500 at $11.52; the first two option tranches are fully vested and exercisable.
Nano-X Imaging Ltd. (NNOX) EVP & Chief Marketing Officer Cohen Tamar Aharon was granted 28,283 restricted share units on October 11, 2026. They vest in four equal semi-annual installments of 25% each on February 13, 2027, August 13, 2027, February 13, 2028 and August 13, 2028, subject to continuous employment on each vesting date. Separate informational holdings list direct options over 33,000, 17,000, 8,000 and 55,000 ordinary shares, with exercise prices of $49.68, $17.63, $17.63 and $11.52, respectively.
Nano-X Imaging Ltd. (NNOX) received Nasdaq notice that its ordinary shares no longer meet the minimum bid-price requirement for continued listing on the Nasdaq Global Market after the closing bid price fell below $1.00 per share for 30 consecutive business days. The company has until March 29, 2027 to regain compliance.
To meet the requirement, the closing bid price must meet or exceed $1.00 per share for at least 10 consecutive business days before that deadline. NNOX said it intends to monitor the closing bid price and consider options to regain compliance; it has made no decision about a response.